148 related articles for article (PubMed ID: 8110878)
1. Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood.
Menzel D; Levi M; Dooijewaard G; Peters M; ten Cate JW
Ann Hematol; 1994 Jan; 68(1):43-8. PubMed ID: 8110878
[TBL] [Abstract][Full Text] [Related]
2. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
[TBL] [Abstract][Full Text] [Related]
3. The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
van de Kar NC; van Hinsbergh VW; Brommer EJ; Monnens LA
Pediatr Res; 1994 Aug; 36(2):257-64. PubMed ID: 7970942
[TBL] [Abstract][Full Text] [Related]
4. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
Louise CB; Obrig TG
Microvasc Res; 1994 May; 47(3):377-87. PubMed ID: 8084301
[TBL] [Abstract][Full Text] [Related]
5. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome.
Bergstein JM; Riley M; Bang NU
N Engl J Med; 1992 Sep; 327(11):755-9. PubMed ID: 1501651
[TBL] [Abstract][Full Text] [Related]
6. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome.
Nevard CH; Jurd KM; Lane DA; Philippou H; Haycock GB; Hunt BJ
Thromb Haemost; 1997 Dec; 78(6):1450-5. PubMed ID: 9423793
[TBL] [Abstract][Full Text] [Related]
7. The role of coagulation and fibrinolysis in the pathogenesis of diarrhea-associated hemolytic uremic syndrome.
Proesmans W
Semin Thromb Hemost; 2001 Jun; 27(3):201-5. PubMed ID: 11446653
[TBL] [Abstract][Full Text] [Related]
8. Association between uremic toxin-anthranilic acid and fibrinolytic system activity in predialysis patients at different stages of chronic kidney disease.
Kaminski TW; Pawlak K; Karbowska M; Mysliwiec M; Grzegorzewski W; Kuna J; Pawlak D
Int Urol Nephrol; 2018 Jan; 50(1):127-135. PubMed ID: 29058166
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period.
Koh CL; Viegas OA; Yuen R; Chua SE; Ng BL; Ratnam SS
Int J Gynaecol Obstet; 1992 May; 38(1):9-18. PubMed ID: 1348996
[TBL] [Abstract][Full Text] [Related]
10. Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Kirchheimer JC; Kölbl H; Tatra G; Binder BR
Eur J Clin Invest; 1990 Feb; 20(1):79-84. PubMed ID: 1690655
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia.
Estellés A; Gilabert J; España F; Aznar J; Galbis M
Am J Obstet Gynecol; 1991 Jul; 165(1):138-42. PubMed ID: 1906680
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
13. Tissue-type plasminogen activator activity in HIV-associated HUS.
Peraldi MN; Maslo C; Berrou J; Rondeau E; Rozenbaum W; Sraer JD
Nephrol Dial Transplant; 1998 Apr; 13(4):919-23. PubMed ID: 9568850
[TBL] [Abstract][Full Text] [Related]
14. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase.
Liebman HA; Carfagno MK; Weitz IC; Berard P; Diiorio JM; Vosburgh E; Simms RW
Am J Clin Pathol; 1992 Nov; 98(5):534-41. PubMed ID: 1485607
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
16. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
[TBL] [Abstract][Full Text] [Related]
17. Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis.
Speiser W; Wojta J; Korninger C; Kirchheimer JC; Zazgornik J; Binder BR
Kidney Int; 1987 Aug; 32(2):280-3. PubMed ID: 3116319
[TBL] [Abstract][Full Text] [Related]
18. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
19. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1.
Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A
Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051
[TBL] [Abstract][Full Text] [Related]
20. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis.
Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH
Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
